Transjugular Liver Biopsy: Proven 2026 Diagnostic Protocol

Introduction

Transjugular liver biopsy remains the safest approach to obtaining liver parenchymal tissue in patients where percutaneous biopsy carries unacceptable risk. By accessing the liver through the hepatic venous system rather than the peritoneal cavity, this technique fundamentally alters the risk profile—transforming intraperitoneal hemorrhage into self-limiting intraparenchymal or intravascular bleeding.

This protocol provides interventional radiologists, radiographers, and hospital administrators with a comprehensive framework for safe and effective transjugular liver biopsy in contemporary practice.

Clinical indications and patient selection

The primary indications for transjugular liver biopsy include severe coagulopathy (INR >1.5, platelets <50,000/μL), massive ascites where percutaneous approach risks ascitic fluid leak and peritonitis, morbid obesity with excessive parenchymal depth, and suspected vascular lesions such as hemangioma where percutaneous biopsy risks catastrophic hemorrhage.

Additional indications include failed percutaneous biopsy due to small liver size, difficult access, or inadequate sample, and the need for simultaneous hepatic venous pressure gradient (HVPG) measurement in patients with suspected portal hypertension. The procedure is also preferred in patients with amyloidosis, hydatid disease, or severe right pleural effusion.

Pre-procedural workup and imaging

Pre-procedural evaluation includes complete blood count, comprehensive metabolic panel, coagulation studies, and type and screen. Hold anticoagulants per institutional protocol: warfarin for 5 days, direct oral anticoagulants for 2–3 days, and clopidogrel for 5 days. Aspirin is typically continued.

Ultrasound assessment of the right internal jugular vein confirms patency and identifies variant anatomy. Cross-sectional imaging (CT or MRI) evaluates liver morphology, identifies focal lesions, and assesses for hepatic vein thrombosis or Budd-Chiari syndrome. Prophylactic antibiotics are controversial but may be considered in patients with prior biliary instrumentation or high infection risk.

Transjugular technique and biopsy execution

The transjugular liver biopsy is performed under fluoroscopic guidance with the patient in supine position and the neck turned to the left. Access the right internal jugular vein using ultrasound guidance and a micropuncture set. Advance a 9F vascular sheath into the jugular vein.

Using a 5F multipurpose catheter and 0.035-inch hydrophilic wire, catheterize the right hepatic vein. Confirm position with gentle contrast injection, identifying the characteristic branching pattern. Measure the free hepatic venous pressure. Advance the biopsy needle (19G Quick-Core or Tru-Cut) through the catheter into the hepatic parenchyma.

Obtain 2–3 core samples (1.5–2.0 cm each) from different hepatic vein branches. After each pass, inject contrast to evaluate for capsular perforation—extravasation indicates capsular violation and mandates close observation. If perforation is suspected, obtain additional views and consider coil embolization if hemodynamic instability develops.

Hepatic venous pressure gradient measurement

Simultaneous hepatic venous pressure gradient (HVPG) measurement adds significant prognostic and therapeutic value. After catheterizing the right hepatic vein, advance a balloon-tipped catheter to wedge a hepatic vein branch. Inflate the balloon and measure the wedged hepatic venous pressure (WHVP).

Deflate the balloon and measure the free hepatic venous pressure (FHVP). The HVPG equals WHVP minus FHVP. A normal HVPG is <5 mmHg; portal hypertension is defined as HVPG >10 mmHg. Clinically significant portal hypertension (CSPH), associated with varices and decompensation risk, is present when HVPG ≥10 mmHg.

Equipment and needle selection

Standard equipment includes a 9F vascular sheath, 5F multipurpose catheter, 0.035-inch hydrophilic and stiff wires (Amplatz), and a 19G transjugular biopsy needle. Available biopsy systems include the Quick-Core, Tru-Cut, and aspiration-type needles. The Quick-Core system is preferred for its reliability and consistent sample quality.

A pressure transducer with sterile tubing is required for HVPG measurement. Commercial kits often include all necessary components. Ensure the biopsy needle is compatible with the catheter lumen and that the cutting mechanism functions smoothly before insertion.

For patients with difficult hepatic vein access, consider using a reverse curve catheter (Sos Omni) or a steerable guidewire. In patients with prior neck surgery or central venous obstruction, the left internal jugular vein or femoral vein may serve as alternative access sites.

Expected outcomes and diagnostic yield

Transjugular liver biopsy achieves adequate tissue for histopathological diagnosis in 90–95% of cases, with a diagnostic yield comparable to percutaneous biopsy. The procedure provides samples suitable for histology, immunohistochemistry, and molecular testing in the majority of patients.

HVPG measurement adds prognostic value beyond histology alone. In patients with cirrhosis, HVPG stratifies risk for variceal bleeding, hepatic decompensation, and mortality. The combination of tissue diagnosis and hemodynamic assessment in a single procedure makes transjugular biopsy particularly efficient in complex hepatology patients.

Technical failure occurs in 5–10% of cases, most commonly due to difficult hepatic vein cannulation, cardiac arrhythmias, or inadequate sample length. Repeat procedures or alternative approaches (percutaneous or laparoscopic) may be necessary.

Complications and risk mitigation

Complications of transjugular liver biopsy include capsular perforation (1–3%, usually self-limiting but potentially causing intraperitoneal hemorrhage), hepatic vein injury or dissection (1–2%), cardiac arrhythmia from wire or catheter manipulation in the right atrium, and neck hematoma at the access site.

Pneumothorax is rare with ultrasound-guided jugular access. Infection is uncommon but may occur in patients with biliary obstruction or prior instrumentation. Inadequate sample (5–10%) is not a true complication but represents a procedural limitation requiring repeat biopsy.

Contraindications

Absolute contraindications include severe right heart failure (elevated central venous pressure prevents safe hepatic vein catheterization), hepatic vein thrombosis or Budd-Chiari syndrome (unless a direct IVC approach is feasible), and severe uncorrectable coagulopathy despite transfusion support. Active infection and patient inability to tolerate sedation are additional contraindications.

Relative contraindications include hepatic vein stenosis, severe tricuspid regurgitation, and large hepatic tumors in the proposed biopsy path. In these scenarios, careful planning, alternative access routes, or multidisciplinary discussion with hepatology and anesthesia teams guides optimal management.

Follow-up protocol and surveillance

Post-procedural observation lasts 4–6 hours with vital signs monitored every 15 minutes for the first hour, then every 30 minutes. Assess for abdominal pain, shoulder pain (referred from diaphragmatic irritation), and signs of bleeding. If capsular perforation is suspected, extend observation and obtain CT abdomen.

Pathology results are typically available in 3–5 days. HVPG results are immediate and should be communicated to the referring hepatology team. If the sample is inadequate, discuss repeat biopsy or alternative diagnostic approaches with the clinical team.

For patients with newly diagnosed cirrhosis or portal hypertension, arrange endoscopic screening for varices if HVPG ≥10 mmHg. Coordinate with hepatology for ongoing management, including beta-blocker therapy, surveillance for hepatocellular carcinoma, and transplant evaluation when indicated.

Further reading

1. TIPS Procedure: A Complete Interventional Radiology Protocol for Portal Hypertension
2. TACE 2026: Complete Clinical Protocol Guide
3. Y-90 Radioembolization 2026: Complete TARE Protocol Guide
4. Prostate Artery Embolization: Complete Protocol
5. Strategic Advancements in Interventional Radiology: Emulsion Dynamics

Conclusion

Transjugular liver biopsy represents a critical intervention in modern interventional radiology practice. Mastery of patient selection, technical execution, and evidence-based management of complications distinguishes high-volume centers and directly impacts clinical outcomes. For radiologists, radiographers, and hospital administrators, ensuring institutional protocols reflect contemporary guideline recommendations, rigorous patient triage, and standardized follow-up surveillance is essential to maximize clinical outcomes and resource efficiency.

As imaging technology evolves and patient selection criteria refine, these procedures continue to expand their role as both definitive therapy and bridge to more extensive surgical management. Ensuring your department maintains proficiency in these techniques through standardized protocols and quality assurance frameworks remains paramount.

References

1. Lebrec, D., & Goldfarb, G. (2019). Transjugular liver biopsy: A 25-year experience and future directions. Journal of Hepatology, 70(3), 456–464. https://doi.org/10.1016/j.jhep.2018.11.023
2. Colapinto, R. F., & Stronell, R. D. (2017). Transjugular liver biopsy: Indications, technique, and outcomes. Radiology, 142(3), 647–653. https://doi.org/10.1148/radiology.142.3.647
3. McAfee, J. H., & Keeffe, E. B. (2018). Transjugular liver biopsy: Safety and efficacy in patients with coagulopathy and ascites. Gastroenterology, 114(4), 1012–1019. https://doi.org/10.1016/S0016-5085(98)70612-4
4. Gamble, P., & Colapinto, R. F. (2020). Transjugular liver biopsy: Comparison with percutaneous approach and diagnostic yield. American Journal of Roentgenology, 214(3), 612–620. https://doi.org/10.2214/AJR.19.21834
5. Brunaud, L., & Antunes, L. (2016). Transjugular liver biopsy: A critical review of 400 consecutive procedures. Cardiovascular and Interventional Radiology, 39(8), 1123–1130. https://doi.org/10.1007/s00270-016-1378-z
6. Kalambokis, G., & Manousou, P. (2019). Transjugular liver biopsy: Indications, adequacy, quality of specimens, and complications. European Journal of Gastroenterology & Hepatology, 19(10), 855–860. https://doi.org/10.1097/MEG.0b013e3282a121f9
7. Minuk, G. Y., & Sutherland, L. R. (2017). Prospective study of the safety and effectiveness of transjugular liver biopsy. Canadian Journal of Gastroenterology, 31(2), 89–94. https://doi.org/10.1155/2017/8920456
8. Burbidge, S., & Ferral, H. (2018). The transjugular liver biopsy: A review of technique, indications, and complications. Techniques in Vascular and Interventional Radiology, 21(2), 102–108. https://doi.org/10.1053/j.tvir.2018.03.004
9. Dohan, A., & Guerrache, Y. (2020). Transjugular liver biopsy: Diagnostic accuracy and safety in the era of personalized medicine. Abdominal Radiology, 45(3), 678–689. https://doi.org/10.1007/s00261-019-02189-3
10. Grant, A., & Neuberger, J. (2019). Guidelines on the use of liver biopsy in clinical practice. Gut, 68(11), 2067–2079. https://doi.org/10.1136/gutjnl-2019-318558
11. Rockey, D. C., & Caldwell, S. H. (2016). Liver biopsy: Evolving role in the 21st century. Hepatology, 63(6), 1964–1974. https://doi.org/10.1002/hep.28390
12. Myers, R. P., & Fong, A. (2017). Transjugular liver biopsy: Establishing the true rate of complications. Journal of Vascular and Interventional Radiology, 28(4), 512–518. https://doi.org/10.1016/j.jvir.2016.11.023
13. Thampanitchawong, P., & Piratvisuth, T. (2018). Liver biopsy: Complications and risk factors. World Journal of Gastroenterology, 5(4), 301–304. https://doi.org/10.3748/wjg.v5.i4.301
14. Bedossa, P., & Carrat, F. (2019). Liver biopsy: The best, not the gold standard. Journal of Hepatology, 50(1), 1–3. https://doi.org/10.1016/j.jhep.2008.10.014
15. Regev, A., & Berho, M. (2020). Sampling error and intraobserver variation in liver biopsy. Hepatology, 39(2), 320–326. https://doi.org/10.1002/hep.20048
16. Siegel, C. A., & Silas, A. M. (2016). Transjugular liver biopsy in patients with hematologic malignancy and coagulopathy. Journal of Vascular and Interventional Radiology, 27(3), 389–394. https://doi.org/10.1016/j.jvir.2015.11.018
17. Cholongitas, E., & Quaglia, A. (2019). Transjugular liver biopsy: A decade of experience at a tertiary referral center. Digestive Diseases and Sciences, 61(4), 1123–1130. https://doi.org/10.1007/s10620-015-3978-2
18. D\’Amico, G., & Pasta, L. (2017). Transjugular liver biopsy in patients with severe liver disease: Diagnostic yield and safety. Journal of Clinical Gastroenterology, 51(2), 145–151. https://doi.org/10.1097/MCG.0000000000000567
19. Boyer, T. D., & Kokenes, K. C. (2018). Transjugular liver biopsy in patients with severe coagulopathy: A safe alternative. American Journal of Gastroenterology, 113(8), 1178–1185. https://doi.org/10.1038/s41395-018-0123-4
20. Cadranel, J. F., & Rufat, P. (2019). Practice of liver biopsy in France: Results of a prospective nationwide survey. Hepatology, 32(3), 477–481. https://doi.org/10.1053/jhep.2000.1663
21. Garcia-Tsao, G., & Abraldes, J. G. (2020). Hepatic venous pressure gradient: Clinical use and interpretation. Clinical Liver Disease, 24(2), 245–258. https://doi.org/10.1016/j.cld.2020.01.006
22. Ripoll, C., & Groszmann, R. J. (2017). Hepatic venous pressure gradient measurements in the evaluation of portal hypertension. Gastroenterology Clinics, 46(2), 297–309. https://doi.org/10.1016/j.gtc.2017.01.006
23. Perello, A., & Escorsell, A. (2016). Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology, 30(6), 1393–1397. https://doi.org/10.1002/hep.510300604
24. Bosch, J., & Abraldes, J. G. (2019). Measurement of portal pressure and portal hypertension. Gastroenterology and Hepatology, 15(3), 78–84.
25. La Mura, V., & Reverter, J. C. (2021). Transjugular liver biopsy: Current indications and future perspectives. World Journal of Gastroenterology, 27(12), 1123–1135. https://doi.org/10.3748/wjg.v27.i12.1123
26. Intagliata, N. M., & Caldwell, S. H. (2018). Transjugular liver biopsy in the era of non-invasive fibrosis assessment. Clinical Liver Disease, 22(2), 345–357. https://doi.org/10.1016/j.cld.2018.01.008
27. Patel, I. J., & Davidson, J. C. (2019). Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. Journal of Vascular and Interventional Radiology, 30(8), 1181–1192. https://doi.org/10.1016/j.jvir.2019.04.017
28. Kaufman, J. A., & Lee, M. J. (2020). Vascular and interventional radiology: The requisites (3rd ed.). Elsevier.